KIMBERLY CLARK CORP
No SEC Form 4 filings for $KMB in the last 30 days.
Kimberly-Clark reported Q1 2026 results on April 28: net sales of $4.2 billion, up 2.7% year over year, with organic sales growing 2.5%. Adjusted operating profit rose 3.7% to $732 million, aided by productivity savings. Adjusted EPS from continuing operations fell 1.2% on tax factors, while total-company adjusted EPS rose 2.1%. The company reaffirmed its 2026 outlook.
Gabelli’s John Belton on CNBC said Mag 7 gains may have been boosted by a “mythos” model and noted AI revenue momentum: Anthropic and OpenAI have an estimated $70B annualized run-rate, up over 2x since year-start. He expects CapEx outlooks to be reiterated in Q1, with cloud revenue a key theme. The article screens NASDAQ stocks with forward P/E <15 and lists JD.com (Q1 2026 net revenues RMB315.7B, +4.9% YoY) and Kimberly-Clark (Q1 2026 net sales $4.2B, +2.7% YoY).
Kimberly-Clark is moving ahead with a hydrogen project at its tissue production facility in Barrow-in-Furness, Cumbria, UK, aiming to reduce natural gas consumption by up to 50% and cut CO2 emissions by approximately 18,300 tonnes. The project, supplied by Carlton Power and Schroders Greencoat, is expected to begin operations in 2028, creating around 200 jobs during construction and 10-15 permanent positions thereafter. This initiative highlights Cumbria's role in the UK's green energy transition and growing hydrogen industry.
